Jul 31, 2025
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
Jul 30, 2025
BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
Jul 22, 2025
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
Jun 26, 2025
BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
Jun 02, 2025
BioArctic's Capital Markets Day 2025 - entering a new era of growth
May 08, 2025
Exidavnemab phase 2a study expanded to include MSA patients
Apr 01, 2025
The European Commission refers lecanemab decision to Appeal Committee
Mar 12, 2025
Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University's Innovation and Entrepreneurship Prize
Mar 03, 2025
Therapeutic Goods Administration decides not to register lecanemab in Australia
Feb 20, 2025
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
Jan 26, 2025
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
Jan 13, 2025
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Dec 05, 2024
First patient dosed in EXIST Phase 2a study in Parkinson's disease
Dec 04, 2024
Leqembi® approved in Mexico
Nov 14, 2024
CHMP issues positive recommendation for approval of lecanemab in the EU
Nov 07, 2024
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
Nov 06, 2024
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET
Nov 06, 2024
BrainTransporter(TM) dramatically improves antibody delivery to the brain
Oct 31, 2024
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Oct 24, 2024
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD